Unicycive Therapeutics, Inc.
Small-molecule therapeutics for kidney disease
- Sector
- Biotech
- Headquarters
- LOS ALTOS, CA
- Founded
- 2016
- Latest Form D
- $50M, Mar 2024
- Total capital
- $81.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $81.7M
- 5 Form D · last Mar 2024
- 31 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 24 pending · first 2022
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$50M
- Private capital raisedForm D · SEC · 4th filing$30.2M
- Private capital raisedForm D · SEC · 3rd filing$604K
- Private capital raisedForm D · SEC · 2nd filing$527K
- Private capital raisedForm D · SEC · 1st filing$420K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Shalabh GuptaResearcherExecutive Officer, DirectorLinked by 2 patents
- Brigitte SchillerDirectorNamed in SEC Form D filings
- Gaurav AggarwalDirectorNamed in SEC Form D filings
- John RyanDirectorNamed in SEC Form D filings
- John TownsendExecutive OfficerNamed in SEC Form D filings
- Sandeep LaumasDirectorNamed in SEC Form D filings
Show all 7 people
- Sara Kenkare-MitraDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 28- PendingNicorandil DerivativesUSPTOApplication 19253368
- PendingLanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate And Methods Of Their Manufacture And UseUSPTOApplication 19225647
- GrantedNicorandil DerivativesUSPTOUS 12,396,989
Show all 28 patent records
- Nicorandil DerivativesApr 30, 2026 · Application 19253368Pending
- Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate And Methods Of Their Manufacture And UseSep 18, 2025 · Application 19225647Pending
- Nicorandil DerivativesAug 26, 2025 · US 12,396,989Granted
- Nicorandil DerivativesAug 5, 2025 · US 12,377,082Granted
- Combinations Containing Oxylanthanum Carbonate For Treating HyperphosphatemiaJul 17, 2025 · Application 19017192Pending
- Pharmaceutical Pyridyl Compositions For Treating And Preventing Delayed Graft FunctionMay 22, 2025 · Application 18947766Pending
- Amino Acid Prodrugs Of NicorandilMay 8, 2025 · Application 18898468Pending
- Salt Forms Of Nicorandil DerivativeJan 2, 2025 · Application 18672454Pending
- Nicorandil DerivativesJul 16, 2024 · US 12,036,211Granted
- Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and UseNov 3, 2022 · Application 17861413Pending
- Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Methods of Their Manufacture and UseAug 9, 2022 · US 11,406,663Granted
- Nicorandil DerivativesMar 17, 2022 · Application 17539146Pending
- Nicorandil DerivativesApplication 63540587Pending
- Salt Forms Of Nicorandil DerivativesApplication 63513800Pending
- Salt Forms Of Nicorandil DerivativeApplication 63504088Pending
- Pharmaceutical Pyridyl Compositions And Methods For UseApplication 63479114Pending
- Pharmaceutical Pyridyl Compositions For Treating And Preventing Delayed Graft FunctionApplication 19586111Pending
- Pyridine Modified Nicorandil DerivativesApplication PCTUS2025020037Pending
- Combinations Containing Oxylanthanum Carbonate For Treating HyperphosphatemiaApplication PCTUS2025011150Pending
- Pharmaceutical Pyridyl Compositions For Treating And Preventing Delayed Graft FunctionApplication PCTUS2024055940Pending
- Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate And Methods Of Their Manufacture And UseApplication 18927494Pending
- Amino Acid Prodrugs Of NicorandilApplication PCTUS2024048708Pending
- Salt Forms Of Nicorandil DerivativesApplication PCTUS2024030751Pending
- Pyridine Modified Nicorandil DerivativesApplication 63565716Pending
- Pharmaceutical Pyridyl Compositions For Treating And Preventing Delayed Graft FunctionApplication 63561059Pending
- Combinations Containing Oxylanthanum Carbonate For Treating HyperphosphatemiaApplication 63620727Pending
- Pharmaceutical Pyridyl Compositions And Methods For UseApplication PCTUS2024010499Pending
- Pharmaceutical Pyridyl Compositions For Treating And Preventing Delayed Graft FunctionApplication 63599665Pending
Related companies, and why
- PRIMROSE BIO, INC.Similar federal contract value in Biotech · null in contracts
- XDEMICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
- Cellares CorpSimilar federal contract value in Biotech · null in contracts
- PURE GREEN PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- KANO THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- METERA PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .